CNTO 530 increases expression of HbA and HbF in murine models of β-thalassemia and sickle cell anemia

Current Pharmaceutical Biotechnology

Volumn 14, Issue 2, 2013, Pages 242-248

  Makropoulos, Dorie A ^a   Achuthanandam, Ram ^a   Avery, Justin ^a   Wilson, Krista ^a   Brosnan, Kerry ^a   Miller, Andrew ^a   Nesspor, Thomas ^a   Chroscinski, Denise ^b   Walker, Mindi ^a   Egenolf, Devon ^a   Huang, Chichi ^a   Bugelski, Peter J ^a  

^a CENTOCOR INC   (United States)

^b Ace Animals Inc   (United States)

Author keywords

Erythropoiesis; Flow cytometry; Fusion protein; Hematology; Ion exchange chromatography; Pharmacodynamics

Indexed keywords

CNTO 530; HEMOGLOBIN; HEMOGLOBIN ALPHA CHAIN; HEMOGLOBIN F; MONOCLONAL ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA THALASSEMIA; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; HEMATOCRIT; HUMAN; MALE; MOUSE; NONHUMAN; RETICULOCYTE; SICKLE CELL ANEMIA; SINGLE DRUG DOSE;

EID: 84875293972     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920113805219449     Document Type: Article

References (34)

1. Jelkmann, W. Erythropoietin after a century of research: younger than ever. Eur. J. Haematol., 2007, 78, 183-205.
2. Bugelski, P.J.; Capocasale, R.J.; Makropoulos, D.; Marshall, D.; Fisher, P.W.; Lu, J.; Achuthanandam, R.; Spinka-Doms, T.; Kwok, D.; Graden, D.; Volk, A.; Nesspor, T.; James, I.E.; Huang, C. CNTO 530: molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice. J. Biotechnol., 2008, 134(1-2), 171-80.
3. Johnson, D.L.; Farrell, F.X.; Barbone, F.P.; McMahon, F.J.; Tullai, J.; Hoey, K.; Livnah, O.; Wrighton, N.C.; Middleton, S.A.; Loughney, D.A.; Stura, E.A.; Dower, W.J.; Mulcahy, L.S.; Wilson, I.A.; L.K.J. Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. Biochemistry, 1998, 37, 3699-3710.
4. Cao, A.; Galanello, R. Beta-thalassemia. Genet. Med., 2010, 12(2), 61-76.
5. Steinberg, M.H. Pathophysiology of sickle cell disease. Baillieres Clin. Haematol., 1998, 11(1), 163-184.
6. Ballas, S.; Marcolina, M. Determinants of red cell survival and erythropoietic activity in patients with sickle cell anemia in the steady state. Hemoglobin., 2000, 24(4), 277-286.
7. Noguchi, C.; Schechter, A.; Rodgers, G. Sickle cell disease pathophysiology. Baillieres Clin. Haematol., 1993, 6(1), 57-91.
8. Al-Khatti, A.; Veith, R.W.; Papayannopoulou, T.; Fritsch, E.F.; Goldwasser, E.; Stamatoyannopoulos, G. Stimulation of fetal hemoglobin synthesis by erythropoietin in baboons. N. Engl. J. Med., 1987, 317(7), 415-420.
9. Yang, B.; Kirby, S.; Lewis. J.; Detloff, P.J.; Maeda, N.; Smithies, O. A mouse model for β-thalassemia. Proc. Natl. Acad. Sci.USA., 1995, 92, 11608-11612.
10. Pászty, C.; Brion, C.; Manci, E.; Witkowska, H.; Stevens, M.; Mohandas, N.; Rubin, E. Transgenic knockout mice with exclusively human hemoglobin and sickle cell disease. Science, 1997, 278, 876-878.
11. Morin, L.; Barton, E. Improved separation of fetal hemoglobin by mini-colum chromatography. Clin. Chem., 1987, 33(2), 288-289.
12. Croizat, H.; Nagel, R. Circulating cytokines response and the level of erythropoiesis in sickle cell anemia. Am. J. Hematol., 1999, 60(2), 105-115.
13. Testa, U. Fetal hemoglobin inducers for treatment of hemoglobinopathies. Ann. Hematol., 2009, 88(6), 505-528.
14. Mabaera, R.; West, R.J.; Conine, S.J.; Macari, E.R.; Boyd, C.D.; Engman, C.A.; Lowrey, C.H. A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger. Exp. Hematol., 2008, 36(9), 1057-1072.
15. Rachmilewitz, E A.; Aker, M. The role of recombinant human erythropoietin in the treatment of thalassemia. Ann. N. Y. Acad., Sci.,1998, 850, 129-138.
16. el-Hazmi, M.A.; al-Momen, A.; Warsy, A.S.; Kandaswamy, S.; Huraib, S.; Harakati, M.; al-Mohareb, F. The pharmacological manipulation of fetal haemoglobin: trials using hydroxyurea and recombinant human erythropoietin. Acta Haematol.,1995, 93(2-4), 57-61.
17. Loukopoulos, D.; Voskaridou, E.; Stamoulakatou, A.; Papassotiriou, Y.; Kalotychou, V.; Loutradi, A.; Cozma, G.; Tsiarta, H.; Pavlides, N. Hydroxyurea therapy in thalassemia. Ann. NY. Acade. Sci.,1998, 850, 120-128.
18. Breymann, C.; Fibach, E.; Visca, E.; Huettner, C.; Huch, A.; Huch, R. Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy. J. Matern. Fetal Med.,1999, 8(1), 1-7.
19. Little, J.A.; McGowan, V.R.; Kato, G.J.; Partovi, K.S.; Feld, J.J.; Maric, I.; Martyr, S.; Taylor, J.G.T.; Machado, R.F.; Heller, T.; Castro, O.; Gladwin, M.T. Combination erythropoietinhydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica, 2006, 91(8), 1076-1083.
20. Perrine, S.P. Fetal globin stimulant therapies in the betahemoglobinopathies: principles and current potential. Pediatr. Ann., 2008, 37(5), 339-346.
21. Schettler, V.; Wieland, E. A case report of darbepoetin treatment in a patient with sickle cell disease and chronic renal failure undergoing regular hemodialysis procedures that induce a dosedependent extension of blood transfusion intervals. Ther. Apher. Dial., 2009, 13(1), 80-82.
22. Stamatoyannopoulos, G.; Umemura, T.; al-Khatti, A.; Spadaccino, E.; Abels, R.I.; Fritsch, E.F.; Papayannopoulou, T. Modulation of HBF production by erythropoietin. Prog. Clin. Biol. Res., 1989, 316B, 269-280.
23. Nagel, R.L.; Vichinsky, E.; Shah, M.; Johnson, R.; Spadacino, E.; Fabry, M. E.; Mangahas, L.; Abel, R.; Stamatoyannopoulos, G. F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study. Blood, 1993, 81(1), 9-14.
24. Rodgers, G.P.; Dover, G.J.; Uyesaka, N.; Noguchi, C.T.; Schechter, A.N.; Nienhuis, A.W. Augmentation by erythropoietin of the fetalhemoglobin response to hydroxyurea in sickle cell disease. N. Engl. J. Med., 1993, 328 (2), 73-80.
25. Bourantas, K.; Economou, G.; Georgiou, J. Administration of high doses of recombinant human erythropoietin to patients with betathalassemia intermedia: a preliminary trial. Eur. J. Haematol., 1997, 58(1), 22-25.
26. Goldberg, M.A.; Brugnara, C.; Dover, G.J.; Schapira, L.; Charache, S.; Bunn, H.F. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N. Engl. J. Med., 1990, 323(6), 366-372.
27. Mahajan, M.; Karmakar, S.; Weissman, S. Control of beta globin genes. J. Cell. Biochem., 2007, 102, 801-810.
28. Testa, U. Apoptotic mechanisms in the control of erythropoiesis. Leukemia, 2004, 18(7), 1176-1199.
29. Richmond, T.D.; Chohan, M.; Barber, D.L. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol., 2005, 15(3), 146-155.
30. Joyeux-Faure, M. Cellular protection by erythropoietin: new therapeutic implications? J. Pharmacol. Exper. Ther., 323(3), 759-762.
31. Allegra, V; Mengozzi, G; Martimbianco, L. Early and late effects of erythropoietin on glucose metabolism in maintenance hemodialysis patients. Am. J. Nephrol., 1996, 16, 304-308.
32. Robach, P.; Recalcati, S.; Girelli, D.; Gelfi, C.; Aachmann- Andersen, N.; Thomsen, J.; Norgaard, A.; Alberghini, A.; Campostrini, N.; Castagna, A.; Viganò, A.; Santambrogio, P.; Kempf, T.; Wollert, K.; Stephane Moutereau, S.; Carsten Lundby, C.; Gaetano Cairo, G., Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin. Blood, 2009, 113, 6707-6715.
33. Livnah, O.; Johnson, D.; Stura, E.; Farrell, F.; Barbone, F.; You, Y.; Liu, K.; Goldsmith, M.; He, W.; Krause, C.; Pestka, S.; Jolliffe, L.; Wilson, I. An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation. Nat. Struc. Biol., 1998, 5, 993-1004.
34. Sathyanarayana, P.; Houde, E.; Marshall, D.; Volk, A.; Makropoulos, D.; Emerson, C.; Pradeep, A.; Bugelski, P. J.; Wojchowski, D. M. CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools. Blood, 2009, 113(20), 4955-4962.